Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon administration of IMC-F106C, the TCR moiety of this agent targets and binds to PRAME on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.

**Synonyms:** - ImmTAC IMC-F106C - ImmTAC Molecule IMC-F106C - Immune Mobilizing Monoclonal TCR Against Cancer IMC-F106C